Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

RYTM – Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals, Inc.
RYTM
$103.27
Name : Rhythm Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $6,859,203,584.00
EPSttm : -3.01
finviz dynamic chart for RYTM
Rhythm Pharmaceuticals, Inc.
$103.27
1.56%
$1.59

Float Short %

7.34

Margin Of Safety %

Put/Call OI Ratio

0.31

EPS Next Q Diff

0.03

EPS Last/This Y

1.39

EPS This/Next Y

0.92

Price

103.29

Target Price

112.5

Analyst Recom

1.13

Performance Q

66.54

Relative Volume

1.02

Beta

2.22

Ticker: RYTM




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25RYTM86.421.035.007607
2025-07-28RYTM85.961.030.227628
2025-07-29RYTM85.670.89999.998288
2025-07-30RYTM84.61.140.437271
2025-07-31RYTM85.261.140.147276
2025-08-01RYTM88.371.140.427284
2025-08-04RYTM90.351.110.067368
2025-08-05RYTM88.561.030.417604
2025-08-06RYTM901.040.197600
2025-08-07RYTM92.481.030.257646
2025-08-08RYTM91.961.030.437646
2025-08-11RYTM94.311.030.027650
2025-08-12RYTM96.440.940.118025
2025-08-13RYTM97.880.950.048022
2025-08-14RYTM96.50.880.198376
2025-08-15RYTM97.720.880.168380
2025-08-18RYTM98.040.370.007825
2025-08-19RYTM97.210.310.008956
2025-08-20RYTM98.650.313.148954
2025-08-21RYTM101.710.310.518956
2025-08-22RYTM103.220.311.208994
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25RYTM86.45-12.3- -2.63
2025-07-28RYTM85.85-21.6- -2.84
2025-07-29RYTM85.63-21.6- -2.84
2025-07-30RYTM84.66-21.6- -2.84
2025-07-31RYTM85.23-21.6- -2.84
2025-08-01RYTM88.30-21.6- -2.84
2025-08-04RYTM90.24-21.6- -2.84
2025-08-05RYTM88.57-21.6- -2.84
2025-08-06RYTM89.96-21.6- -2.84
2025-08-07RYTM92.48-21.6- -2.84
2025-08-08RYTM91.983.7- -2.95
2025-08-11RYTM94.393.7- -2.95
2025-08-12RYTM96.473.8- -2.94
2025-08-13RYTM97.863.4- -2.94
2025-08-14RYTM96.523.4- -2.95
2025-08-15RYTM97.723.4- -2.95
2025-08-18RYTM98.093.4- -2.95
2025-08-19RYTM97.193.4- -2.95
2025-08-20RYTM98.703.4- -2.95
2025-08-21RYTM101.713.4- -2.95
2025-08-22RYTM103.293.4- -2.95
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25RYTM-6.370.417.97
2025-07-28RYTM-6.370.297.97
2025-07-29RYTM-6.370.297.97
2025-07-30RYTM-6.400.297.97
2025-07-31RYTM-6.400.297.97
2025-08-01RYTM-6.400.297.97
2025-08-04RYTM-6.400.427.97
2025-08-05RYTM-6.250.427.97
2025-08-06RYTM-6.250.427.97
2025-08-07RYTM-6.250.427.97
2025-08-08RYTM-6.130.427.88
2025-08-11RYTM-6.130.497.89
2025-08-12RYTM-6.010.497.43
2025-08-13RYTM-6.010.497.43
2025-08-14RYTM-6.070.497.43
2025-08-15RYTM-6.470.497.43
2025-08-18RYTM-6.470.537.45
2025-08-19RYTM-6.310.537.35
2025-08-20RYTM-6.970.537.35
2025-08-21RYTM-6.970.537.34
2025-08-22RYTM-7.100.537.34
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.75

Avg. EPS Est. Current Quarter

-0.7

Avg. EPS Est. Next Quarter

-0.72

Insider Transactions

-7.1

Institutional Transactions

0.53

Beta

2.22

Average Sales Estimate Current Quarter

50

Average Sales Estimate Next Quarter

54

Fair Value

Quality Score

43

Growth Score

39

Sentiment Score

91

Actual DrawDown %

-1.5

Max Drawdown 5-Year %

-92.1

Target Price

112.5

P/E

Forward P/E

PEG

P/S

43.89

P/B

P/Free Cash Flow

EPS

-3.02

Average EPS Est. Cur. Y​

-2.95

EPS Next Y. (Est.)

-2.03

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-120.55

Relative Volume

1.02

Return on Equity vs Sector %

-165.8

Return on Equity vs Industry %

-152.8

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.11

EBIT Estimation

Rhythm Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 283
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.
stock quote shares RYTM – Rhythm Pharmaceuticals Inc. Stock Price stock today
news today RYTM – Rhythm Pharmaceuticals Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RYTM – Rhythm Pharmaceuticals Inc. yahoo finance google finance
stock history RYTM – Rhythm Pharmaceuticals Inc. invest stock market
stock prices RYTM premarket after hours
ticker RYTM fair value insiders trading